These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 38045044)

  • 21. Riluzole enhances the antitumor effects of temozolomide via suppression of MGMT expression in glioblastoma.
    Yamada T; Tsuji S; Nakamura S; Egashira Y; Shimazawa M; Nakayama N; Yano H; Iwama T; Hara H
    J Neurosurg; 2021 Mar; 134(3):701-710. PubMed ID: 32168477
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Infiltration of CD163-positive macrophages in glioma tissues after treatment with anti-PD-L1 antibody and role of PI3Kγ inhibitor as a combination therapy with anti-PD-L1 antibody in in vivo model using temozolomide-resistant murine glioma-initiating cells.
    Miyazaki T; Ishikawa E; Matsuda M; Sugii N; Kohzuki H; Akutsu H; Sakamoto N; Takano S; Matsumura A
    Brain Tumor Pathol; 2020 Apr; 37(2):41-49. PubMed ID: 31980975
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Aspirin Affects Tumor Angiogenesis and Sensitizes Human Glioblastoma Endothelial Cells to Temozolomide, Bevacizumab, and Sunitinib, Impairing Vascular Endothelial Growth Factor-Related Signaling.
    Navone SE; Guarnaccia L; Cordiglieri C; Crisà FM; Caroli M; Locatelli M; Schisano L; Rampini P; Miozzo M; La Verde N; Riboni L; Campanella R; Marfia G
    World Neurosurg; 2018 Dec; 120():e380-e391. PubMed ID: 30144594
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effect of axitinib regulating the pathological blood-brain barrier functional recovery for glioblastoma therapeutics.
    Zhang F; Wen L; Wang K; Huang Z; Jin X; Xiong R; He S; Hu F
    CNS Neurosci Ther; 2022 Mar; 28(3):411-421. PubMed ID: 34967104
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Preclinical modeling in glioblastoma patient-derived xenograft (GBM PDX) xenografts to guide clinical development of lisavanbulin-a novel tumor checkpoint controller targeting microtubules.
    Burgenske DM; Talele S; Pokorny JL; Mladek AC; Bakken KK; Carlson BL; Schroeder MA; He L; Hu Z; Gampa G; Kosel ML; Decker PA; Kitange GJ; Schmitt-Hoffmann A; Bachmann F; Vaubel RA; Eckel-Passow JE; Giannini C; McSheehy P; Lane HA; Elmquist WF; Sarkaria JN
    Neuro Oncol; 2022 Mar; 24(3):384-395. PubMed ID: 34232318
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Piperlongumine conquers temozolomide chemoradiotherapy resistance to achieve immune cure in refractory glioblastoma via boosting oxidative stress-inflamation-CD8
    Liu F; Zhou Q; Jiang HF; Zhang TT; Miao C; Xu XH; Wu JX; Yin SL; Xu SJ; Peng JY; Gao PP; Cao X; Pan F; He X; Chen XQ
    J Exp Clin Cancer Res; 2023 May; 42(1):118. PubMed ID: 37161450
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pharmacological inhibition of serine synthesis enhances temozolomide efficacy by decreasing O
    Jin L; Kiang KM; Cheng SY; Leung GK
    Lab Invest; 2022 Feb; 102(2):194-203. PubMed ID: 34625658
    [TBL] [Abstract][Full Text] [Related]  

  • 28. p53 Small-molecule inhibitor enhances temozolomide cytotoxic activity against intracranial glioblastoma xenografts.
    Dinca EB; Lu KV; Sarkaria JN; Pieper RO; Prados MD; Haas-Kogan DA; Vandenberg SR; Berger MS; James CD
    Cancer Res; 2008 Dec; 68(24):10034-9. PubMed ID: 19074867
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Differential gene expression-based connectivity mapping identified novel drug candidate and improved Temozolomide efficacy for Glioblastoma.
    Vengoji R; Atri P; Macha MA; Seshacharyulu P; Perumal N; Mallya K; Liu Y; Smith LM; Rachagani S; Mahapatra S; Ponnusamy MP; Jain M; Batra SK; Shonka N
    J Exp Clin Cancer Res; 2021 Oct; 40(1):335. PubMed ID: 34696786
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Modulating lncRNA SNHG15/CDK6/miR-627 circuit by palbociclib, overcomes temozolomide resistance and reduces M2-polarization of glioma associated microglia in glioblastoma multiforme.
    Li Z; Zhang J; Zheng H; Li C; Xiong J; Wang W; Bao H; Jin H; Liang P
    J Exp Clin Cancer Res; 2019 Aug; 38(1):380. PubMed ID: 31462285
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pharmacologic inhibition of cyclin-dependent kinases 4 and 6 arrests the growth of glioblastoma multiforme intracranial xenografts.
    Michaud K; Solomon DA; Oermann E; Kim JS; Zhong WZ; Prados MD; Ozawa T; James CD; Waldman T
    Cancer Res; 2010 Apr; 70(8):3228-38. PubMed ID: 20354191
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Repurposing an Antiepileptic Drug for the Treatment of Glioblastoma.
    Yadav A; Alnakhli A; Vemana HP; Bhutkar S; Muth A; Dukhande VV
    Pharm Res; 2022 Nov; 39(11):2871-2883. PubMed ID: 36195821
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A hypoxia-dissociable siRNA nanoplatform for synergistically enhanced chemo-radiotherapy of glioblastoma.
    Xie Y; Lu X; Wang Z; Liu M; Liu L; Wang R; Yang K; Xiao H; Li J; Tang X; Liu H
    Biomater Sci; 2022 Nov; 10(23):6791-6803. PubMed ID: 36314541
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Albumin-bound paclitaxel augment temozolomide treatment sensitivity of glioblastoma cells by disrupting DNA damage repair and promoting ferroptosis.
    Qu S; Qi S; Zhang H; Li Z; Wang K; Zhu T; Ye R; Zhang W; Huang G; Yi GZ
    J Exp Clin Cancer Res; 2023 Oct; 42(1):285. PubMed ID: 37891669
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Alantolactone, a natural sesquiterpene lactone, has potent antitumor activity against glioblastoma by targeting IKKβ kinase activity and interrupting NF-κB/COX-2-mediated signaling cascades.
    Wang X; Yu Z; Wang C; Cheng W; Tian X; Huo X; Wang Y; Sun C; Feng L; Xing J; Lan Y; Sun D; Hou Q; Zhang B; Ma X; Zhang B
    J Exp Clin Cancer Res; 2017 Jul; 36(1):93. PubMed ID: 28701209
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Temporary blood-brain barrier disruption by low intensity pulsed ultrasound increases carboplatin delivery and efficacy in preclinical models of glioblastoma.
    Dréan A; Lemaire N; Bouchoux G; Goldwirt L; Canney M; Goli L; Bouzidi A; Schmitt C; Guehennec J; Verreault M; Sanson M; Delattre JY; Mokhtari K; Sottilini F; Carpentier A; Idbaih A
    J Neurooncol; 2019 Aug; 144(1):33-41. PubMed ID: 31197598
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Identification of compound D2923 as a novel anti-tumor agent targeting CSF1R.
    Liu YQ; Wang YN; Lu XY; Tong LJ; Li Y; Zhang T; Xun QJ; Feng F; Chen YZ; Su Y; Shen YY; Chen Y; Geng MY; Ding K; Li YL; Xie H; Ding J
    Acta Pharmacol Sin; 2018 Nov; 39(11):1768-1776. PubMed ID: 29968849
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A Chimeric Antibody against ACKR3/CXCR7 in Combination with TMZ Activates Immune Responses and Extends Survival in Mouse GBM Models.
    Salazar N; Carlson JC; Huang K; Zheng Y; Oderup C; Gross J; Jang AD; Burke TM; Lewén S; Scholz A; Huang S; Nease L; Kosek J; Mittelbronn M; Butcher EC; Tu H; Zabel BA
    Mol Ther; 2018 May; 26(5):1354-1365. PubMed ID: 29606504
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Dual-targeting immunoliposomes using angiopep-2 and CD133 antibody for glioblastoma stem cells.
    Kim JS; Shin DH; Kim JS
    J Control Release; 2018 Jan; 269():245-257. PubMed ID: 29162480
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Intranasal Delivery of Temozolomide-Conjugated Gold Nanoparticles Functionalized with Anti-EphA3 for Glioblastoma Targeting.
    Wang L; Tang S; Yu Y; Lv Y; Wang A; Yan X; Li N; Sha C; Sun K; Li Y
    Mol Pharm; 2021 Mar; 18(3):915-927. PubMed ID: 33417456
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.